|
1
|
Islami F, Torre LA and Jemal A: Global
trends of lung cancer mortality and smoking prevalence. Transl Lung
Cancer Res. 4:327–338. 2015.PubMed/NCBI
|
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Temel JS, Greer JA, Muzikansky A,
Gallagher ER, Admane S, Jackson VA, Dahlin CM, Blinderman CD,
Jacobsen J, Pirl WF, et al: Early palliative care for patients with
metastatic non-small cell lung cancer. N Engl J Med. 363:733–742.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zimmermann C, Swami N, Krzyżanowska M,
Hannon B, Leighl N, Oza A, Moore M, Rydall A, Rodin G, Tannock I,
et al: Early palliative care for patients with advanced cancer: A
cluster-randomised controlled trial. Lancet. 383:1721–1730. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
King JD, Eickhoff J, Traynor A and
Campbell TC: Integrated onco-palliative care associated with
prolonged survival compared to standard care for patients with
advanced lung cancer: A retrospective review. J Pain Symptom
Manage. 51:1027–1032. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Temel JS, Greer JA, El-Jawahri A, Pirl WF,
Park ER, Jackson VA, Back AL, Kamdar M, Jacobsen J, Chittenden EH,
et al: Effects of early palliative care in patients with lung and
GI cancer: A randomized clinical trial. J Clin Oncol. 35:834–841.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
National Comprehensive Cancer Network
(NCCN): NCCN Guidelines-Non-small Cell Lung Cancer, Version 3.2020.
simplehttps://www.nccn.org/globalFebruary 11–2020
|
|
8
|
Planchard D, Popat S, Kerr K, Novello S,
Smit EF, Faivre-Finn C, Mok TS, Reck M, Van Schil PE, Hellmann MD,
et al: Metastatic non-small cell lung cancer: ESMO clinical
practice guidelines for diagnosis, treatment and follow-up. Ann
Oncol. 30:863–870. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Reck M, Rodríguez-Abreu D, Robinson AG,
Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe
S, et al KEYNOTE-024 Investigators, : Pembrolizumab versus
chemotherapy for PD-L1-positive non-small cell lung cancer. N Engl
J Med. 375:1823–1833. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Reck M, Rodríguez-Abreu D, Robinson AG,
Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe
S, et al: Updated analysis of KEYNOTE-024: Pembrolizumab versus
platinum-based chemotherapy for advanced non-small cell lung cancer
with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol.
37:537–546. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Brahmer JR, Rodríguez-Abreu D, Robinson
AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A,
Cuffe S, et al: Health-related quality-of-life results for
pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC
(KEYNOTE-024): A multicentre, international, randomised, open-label
phase 3 trial. Lancet Oncol. 18:1600–1609. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gadgeel S, Rodríguez-Abreu D, Speranza G,
Esteban E, Felip E, Dómine M, Hui R, Hochmair MJ, Clingan P, Powell
SF, et al: Updated analysis from KEYNOTE-189: Pembrolizumab or
placebo plus pemetrexed and platinum for previously untreated
metastatic nonsquamous non-small cell lung cancer. J Clin Oncol.
38:1505–1517. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Garassino M, Rodriguez-Abreu D, Gadgeel,
Esteban E, Felip E, De Angelis F, Domine M, Hochmair M, Powell SF,
Cheng SY, et al: Health-related quality of life (HRQoL) in the
KEYNOTE-189 study of pembrolizumab (pembro) or placebo (pbo) +
pemetrexed (pem) + platinum (plt) for metastatic NSCLC. J Clin
Oncol. 36:2019.
|
|
14
|
Hellmann MD, Ciuleanu TE, Pluzanski A, Lee
JS, Otterson GA, Audigier-Valette C, Minenza E, Linardou H, Burgers
S, Salman P, et al: Nivolumab plus ipilimumab in lung cancer with a
high tumor mutational burden. N Engl J Med. 378:2093–2104. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hellmann MD, Paz-Ares L, Bernabe Caro R,
Zurawski B, Kim SW, Carcereny Costa E, Park K, Alexandru A,
Lupinacci L, de la Mora Jimenez E, et al: Nivolumab plus Ipilimumab
in advanced non-small cell lung cancer. N Engl J Med.
381:2020–2031. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Reck M, Schenker M, Lee KH, Provencio M,
Nishio M, Lesniewski-Kmak K, Sangha R, Ahmed S, Raimbourg J, Feeney
K, et al: Nivolumab plus ipilimumab versus chemotherapy as
first-line treatment in advanced non-small cell lung cancer with
high tumour mutational burden: Patient-reported outcomes results
from the randomised, open-label, phase III CheckMate 227 trial. Eur
J Cancer. 116:137–147. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Socinski MA, Jotte RM, Cappuzzo F, Orlandi
F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D,
Thomas CA, Barlesi F, et al IMpower150 study group, : Atezolizumab
for first-line treatment of metastatic nonsquamous NSCLC. N Engl J
Med. 378:2288–2301. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Reck M, Wehler T, Orlandi F, Nogami N,
Barone C, Moro-Sibilot D, Shtivelband M, González Larriba JL,
Rothenstein J, Früh M, et al: Safety and patient-reported outcomes
of atezolizumab plus chemotherapy with or without bevacizumab
versus bevacizumab plus chemotherapy in non-small cell lung Cancer.
J Clin Oncol. 38:2530–2542. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Brahmer J, Reckamp KL, Baas P, Crinò L,
Eberhardt WEE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE,
Holgado E, et al: Nivolumab versus docetaxel in advanced
squamous-cell non-small cell lung cancer. N Engl J Med.
373:123–135. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Reck M, Taylor F, Penrod JR, DeRosa M,
Morrissey L, Dastani H, Orsini L and Gralla RJ: Impact of nivolumab
versus docetaxel on health-related quality of life and symptoms in
patients with advanced squamous non-small cell lung cancer: Results
from the CheckMate 017 study. J Thorac Oncol. 13:194–204. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Borghaei H, Paz-Ares L, Horn L, Spigel DR,
Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al:
Nivolumab versus docetaxel in advanced nonsquamous non-small cell
lung cancer. N Engl J Med. 373:1627–1639. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Reck M, Brahmer J, Bennett B, Taylor F,
Penrod JR, DeRosa M, Dastani H, Spigel DR and Gralla RJ: Evaluation
of health-related quality of life and symptoms in patients with
advanced non-squamous non-small cell lung cancer treated with
nivolumab or docetaxel in CheckMate 057. Eur J Cancer. 102:23–30.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Herbst RS, Baas P, Kim DW, Felip E,
Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, et al:
Pembrolizumab versus docetaxel for previously treated,
PD-L1-positive, advanced non-small cell lung cancer (KEYNOTE-010):
A randomised controlled trial. Lancet. 387:1540–1550. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Barlesi F, Garon EB, Kim DW, Felip E, Han
JY, Kim JH, Ahn MJ, Fidler MJ, Gubens MA, de Castro G Jr, et al:
Health-related quality of life in KEYNOTE-010: A phase II/III study
of pembrolizumab versus docetaxel in patients with previously
treated advanced, programmed death ligand 1-expressing NSCLC. J
Thorac Oncol. 14:793–801. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rittmeyer A, Barlesi F, Waterkamp D, Park
K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols
MC, et al OAK study group, : Atezolizumab versus docetaxel in
patients with previously treated non-small cell lung cancer (OAK):
A phase 3, open-label, multicentre randomised controlled trial.
Lancet. 389:255–265. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bordoni R, Ciardiello F, von Pawel J,
Cortinovis D, Karagiannis T, Ballinger M, Sandler A, Yu W, He P,
Matheny C, et al: Patient-reported outcomes in OAK: A phase III
study of atezolizumab versus docetaxel in advanced non-small cell
lung cancer. Clin Lung Cancer. 19:441–449.e4. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Temel JS, Greer JA, Muzikansky A,
Gallagher ER, Admane S, Jackson VA, Dahlin CM, Blinderman CD,
Jacobsen J, Pirl WF, et al: Early palliative care for patients with
metastatic non-small cell lung cancer. N Engl J Med. 363:733–742.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Smith TJ, Temin S, Alesi ER, Abernethy AP,
Balboni TA, Basch EM, Ferrell BR, Loscalzo M, Meier DE, Paice JA,
et al: American society of clinical oncology provisional clinical
opinion: The integration of palliative care into standard oncology
care. J Clin Oncol. 30:880–887. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Irwin KE, Greer JA, Khatib J, Temel JS and
Pirl WF: Early palliative care and metastatic non-small cell lung
cancer: Potential mechanisms of prolonged survival. Chron Respir
Dis. 10:35–47. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Saito AM, Landrum MB, Neville BA, Ayanian
JZ and Earle CC: The effect on survival of continuing chemotherapy
to near death. BMC Palliat Care. 10:142011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Watsob MS, Lucas CF, Hoy AM and Back IN:
Oxford Handbook of Palliative Care. 1st edition. Oxford University
Press; Oxford: 2005
|
|
32
|
Zajączkowska R, Leppert W, Mika J,
Kocot-Kępska M, Woroń J, Wrzosek A and Wordliczek J: Perioperative
immunosuppression and risk of cancer progression: The impact of
opioids on pain management. Pain Res Manag. 2018:92937042018.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Rinaldi S, Marcantognini G, Fiordoliva I,
di Pietro Paolo M, Morgese F, Toriniai M, Burattini L and Berardi
R: The negative prognostic role of opioids in patients with NSCLC
treated with immunotherapy. Presented at MASCC/ISOO Annual Meeting
on Supportive Care in Cancer San Francisco, CA: 2019
|
|
34
|
Bironzo P, Pignataro D, Audisio M,
Tagliamento M, Paratore C, Tabbò F, Bungaro M, Zichi C, Filippis M,
Rapetti S, et al: Association between opioids and outcome of 1st
line immunotherapy in advanced NSCLC patients: A retrospective
evaluation. JTO. 14:s7132019.
|
|
35
|
Arbour KC, Mezquita L, Long N, Rizvi H,
Auclin E, Ni A, Martínez-Bernal G, Ferrara R, Lai WV, Hendriks LEL,
et al: Impact of baseline steroids on efficacy of programmed cell
death-1 and programmed death-ligand 1 blockade in patients with
non–small cell lung cancer. J Clin Oncol. 36:2872–2878. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
De Giglio A, Mezquita L, Auclin E,
Blanc-Durand F, El-Amarti L, Caramella C, Martinez Bernal G,
Hendriks L, Ferrara R, Naltet C, et al: Impact of early
introduction of steroid on immune-checkpoint inhibitors (ICI) in
patients with advanced non- small cell lung cancer treated. Ann
Oncol. 30((s11)): xi162019. View Article : Google Scholar
|
|
37
|
Shih A and Jackson KC II: Role of
corticosteroids in palliative care. J Pain Palliat Care
Pharmacother. 21:69–76. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Barghi K, Edmonds KP, Ajayi TA and Atayee
RB: Prescribing trends of palliative care teams use of
dexamethasone for cancer-related pain. J Pain Palliat Care
Pharmacother. 32:37–43. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
North West Clinical Senates: Guidelines
for the use of corticosteroids in palliative care. simplehttp://www.nwcscnsenate.nhs.uk/files/2814/3394/6186/Corticosterioids.pdfMay
18–2020
|
|
40
|
Lozupone CA, Stombaugh JI, Gordon JI,
Jansson JK and Knight R: Diversity, stability and resilience of the
human gut microbiota. Nature. 489:220–230. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zitvogel L, Ayyoub M, Routy B and Kroemer
G: Microbiome and anticancer immunosurveillance. Cell. 165:276–287.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ubeda C and Pamer EG: Antibiotics,
microbiota, and immune defense. Trends Immunol. 33:459–466. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Lange K, Buerger M, Stallmach A and Bruns
T: Effects of antibiotics on gut microbiota. Dig Dis. 34:260–268.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Derosa L, Hellmann MD, Spaziano M,
Halpenny D, Fidelle M, Rizvi H, Long N, Plodkowski AJ, Arbour KC,
Chaft JE, et al: Negative association of antibiotics on clinical
activity of immune checkpoint inhibitors in patients with advanced
renal cell and non-small cell lung cancer. Ann Oncol. 29:1437–1444.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Rosenberg JH, Albrecht JS, Fromme EK,
Noble BN, McGregor JC, Comer AC and Furuno JP: Antimicrobial use
for symptom management in patients receiving hospice and palliative
care: A systematic review. J Palliat Med. 16:1568–1574. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Helde-Frankling M, Bergqvist J, Bergman P
and Björkhem-Bergman L: Antibiotic treatment in end-of-life cancer
patients-A retrospective observational study at a palliative care
center in Sweden. Cancers (Basel). 8:842016. View Article : Google Scholar
|
|
47
|
Juthani-Mehta M, Malani PN and Mitchell
SL: Antimicrobials at the end of life: An opportunity to improve
palliative care and infection management. JAMA. 314:2017–2018.
2015. View Article : Google Scholar : PubMed/NCBI
|
